2022
Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdults
2021
Evaluation of Web-Based and In-Person Methods to Recruit Adults With Type 1 Diabetes for a Mobile Exercise Intervention: Prospective Observational Study
Ash GI, Griggs S, Nally LM, Stults-Kolehmainen M, Jeon S, Brandt C, Gulanski BI, Spanakis EK, Baker JS, Whittemore R, Weinzimer SA, Fucito LM. Evaluation of Web-Based and In-Person Methods to Recruit Adults With Type 1 Diabetes for a Mobile Exercise Intervention: Prospective Observational Study. JMIR Diabetes 2021, 6: e28309. PMID: 34047700, PMCID: PMC8299346, DOI: 10.2196/28309.Peer-Reviewed Original ResearchType 1 diabetesEligible volunteersExercise interventionClinical trialsIncremental costProspective observational studyGreater New HavenCharacteristics of enrolleesHigh-risk participantsOlder patientsOverall cohortPatients 18Clinical visitsUncommon conditionAdults 18Observational studySnowball samplingActive adultsT1DEligibility screeningPrior trialsLower click ratesPatientsActive individualsEligibility rates214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised Trial
FUCHS J, BOUGHTON C, ALLEN J, WILINSKA M, TAUSCHMANN M, DENVIR L, THANKAMONY A, CAMPBELL F, WADWA R, BUCKINGHAM B, DAVIS N, DIMEGLIO L, MAURAS N, BESSER R, GHATAK A, WEINZIMER S, HOOD K, FOX D, KANAPKA L, KOLLMAN C, SIBAYAN J, BECK R, HOVORKA R. 214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised Trial. Diabetes 2021, 70 DOI: 10.2337/db21-214-or.Peer-Reviewed Original Research51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D
HUGHES A, CHAPMAN K, BISPHAM J, HEYDARIAN N, DIMSITS J, WEINZIMER S, WOLF W. 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D. Diabetes 2021, 70 DOI: 10.2337/db21-51-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaGlucagon useMini-dose glucagonUse of glucagonSevere hypoglycemic eventsEase of administrationOvernight hypoglycemiaGlycemic targetsHypoglycemia unawarenessHypoglycemic eventsPrescription costsSleep disruptorsTreatment decisionsNasal administrationHypoglycemiaDiabetes managementFocus groupsGlucagon actionGlucagon treatmentGlucagonEmotional impactAverage durationT1DPerspectives of peopleSpeakers bureauPredictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD, Gonder-Frederick L, Robic J, Voelmle M, Conschafter K, Morris K, Barnett C, Carr K, Hellmann J, Kime M, Todd Alonso G, Slover R, Berget C, Towers L, Lange S, Buckingham B, Maahs D, Lal R, Ekhlaspour L, Norlander L, Hood K, Town M, Weir C, Smith K, Hsu L, Shinksy D, Viana J, Cengiz E, Weinzimer S, Weyman K, Carria L, Zgorski M, Ruedy K, Beck R, Borgman S, Rusnak J, Kanapka L, Kollman C, Murphy C, Arreza-Rubin G, Green N, Kovatchev B, Brown S, Anderson S, Breton M, Laffel L, Pinsker J, Levy C, Kudva Y, Wadwa R, Buckingham B, Doyle III F, Renard E, Cobelli C, Reznik Y, Arreza-Rubin G, Lum J, Beck R, Ruedy K, Janicek R, Gabrielson D. Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technology & Therapeutics 2021, 23: 475-481. PMID: 33689454, PMCID: PMC8252894, DOI: 10.1089/dia.2020.0646.Peer-Reviewed Original ResearchConceptsGlycemic controlLower TIROptimal glycemic controlType 1 diabetesPredictors of timeGreater improvementClinical characteristicsClinical predictorsFourth quartileMore insulinBody weightGlucose monitor dataExtension phaseMultivariate modelBolusStrongest predictorContinuous glucose monitor dataQuartileInsulinPredictorsChildrenParticipantsT1D.T1DDiabetesAutomated Insulin Delivery
Weinzimer S, Carria L, Van Name M. Automated Insulin Delivery. Contemporary Endocrinology 2021, 75-85. DOI: 10.1007/978-3-030-64133-7_8.ChaptersDiabetes self-management tasksInsulin deliveryHemoglobin A1c levelsT1D Exchange RegistrySelf-management tasksGlycemic targetsA1c levelsDiabetes careContinuous glucose monitoring devicesDiabetes therapyInsulin pumpGlucose monitoring devicesDiabetes technologyRecent dataMost youthMore burdenDiabetes devicesBurdenDeliveryT1DRegistryTherapy
2020
8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D
HUGHES A, BISPHAM J, FULLER L, WOLF W, FITCH S, WEINZIMER S. 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D. Diabetes 2020, 69 DOI: 10.2337/db20-8-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaPerspectives of peopleUse of glucagonAdministration of glucagonMinimal side effectsMode of administrationHypoglycemic emergenciesGlycemic targetsInsulin therapyDiabetes careSpouse/partnerEmergency treatmentEffective treatmentHypoglycemiaSide effectsT1DGlucagonEmotional impactEmergency useCaregiversT1D.Administration typeFeelings of distressAdministrationParticipants998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents
ROETHKE L, COMMISSARIAT P, FINNEGAN J, VOLKENING L, BUTLER D, DASSAU E, WEINZIMER S, LAFFEL L. 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents. Diabetes 2020, 69 DOI: 10.2337/db20-998-p.Peer-Reviewed Original ResearchDiabetes careT1D durationInsulin pumpType 1 diabetesBoehringer Ingelheim PharmaceuticalsSanofi USDiabetes CenterDifferent treatment situationsSpouse/partnerInsulin delivery systemsCare burdenGlucose levelsJanssen PharmaceuticalsT1DArtificial pancreas systemsDiabetesEmotional burdenParents of youthYoung adultsSpeakers bureauCareAge 10Emotional distressNational InstituteUnderwent content analysis
2019
816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D)
COMMISSARIAT P, ROETHKE L, VOLKENING L, BUTLER D, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-816-p.Peer-Reviewed Original ResearchDiabetes careBurden of T1DSelf-care burdenDiabetes technologyType 1 diabetesEli LillyArtificial pancreasUnderwent thematic analysisT1D durationNovo Nordisk A/SCarbohydrate countingSpouse/partnerCare burdenSemi-structured qualitative interviewsT1D careJanssen PharmaceuticalsMedtronic MiniMedPatients' hopeAP uptakeHeart rate monitorT1DDiabetesYoung adultsSpeakers bureauCare817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey
COMMISSARIAT P, VOLKENING L, ROETHKE L, GUO Z, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey. Diabetes 2019, 68 DOI: 10.2337/db19-817-p.Peer-Reviewed Original ResearchDiabetes careYoung personLess diabetes distressType 1 diabetesEli LillyInternal consistencyAdvanced diabetes technologiesMale sexDiabetes distressNovo Nordisk A/SSpouse/partnerGood internal consistencyT1D careDiabetesJanssen PharmaceuticalsMedtronic MiniMedMultidisciplinary teamTreatment surveySignificant associationPsychosocial outcomesYouth ages 8T1DCeiling effectsTotal scoreIllness identity
2018
Longitudinal assessment of hippocampus structure in children with type 1 diabetes
Foland‐Ross L, Reiss AL, Mazaika PK, Mauras N, Weinzimer SA, Aye T, Tansey MJ, White NH, Network T. Longitudinal assessment of hippocampus structure in children with type 1 diabetes. Pediatric Diabetes 2018, 19: 1116-1123. PMID: 29675980, PMCID: PMC6195484, DOI: 10.1111/pedi.12683.Peer-Reviewed Original ResearchAge-matched control subjectsType 1 diabetes mellitusHealthy age-matched controlsEffects of dysglycemiaEffect of diabetesRisk of hypoglycemiaHealthy control childrenType 1 diabetesAge-matched controlsGreater glycemic variabilityYoung childrenStructural magnetic resonance imaging (MRI) dataGlycemic exposureDiabetes mellitusControl subjectsGlycemic variabilityHippocampal volumeMagnetic resonance imaging dataHippocampus volumeCognitive alterationsHippocampus structureT1DControl childrenLongitudinal assessmentLongitudinal changes
2017
Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System
Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Science Of Diabetes Self-Management And Care 2017, 43: 223-232. PMID: 28340542, PMCID: PMC7162535, DOI: 10.1177/0145721717697244.Peer-Reviewed Original ResearchConceptsType 1 diabetesHybrid closed-loop systemFirst hybrid closed-loop systemLong-term complicationsGlycemic controlClinical trialsUS FoodDrug AdministrationMethods ThirtyDiabetesLife benefitsInsulin deliveryMental burdenT1DArtificial pancreasConclusion UsersAttitudes of individualsFocus groupsPerceived benefitsIndividualsComplicationsPancreasCliniciansAdministrationTrials
2016
Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes
Hosseini SM, Mazaika P, Mauras N, Buckingham B, Weinzimer SA, Tsalikian E, White NH, Reiss AL, Network F. Altered Integration of Structural Covariance Networks in Young Children With Type 1 Diabetes. Human Brain Mapping 2016, 37: 4034-4046. PMID: 27339089, PMCID: PMC5053865, DOI: 10.1002/hbm.23293.Peer-Reviewed Original ResearchConceptsEarly-onset T1DStructural covariance networksYoung childrenNeurocognitive deficitsType 1 diabetes mellitusCovariance networksBrain networksFrequent chronic diseasesHum Brain MappRegional gray matterGlycemic controlDiabetes mellitusGlucose dysregulationNeural insultsHealthy controlsLarge-scale brain networksChronic diseasesBulk of evidenceNeuroanatomical changesT1DWhite matterGray matterBrain developmentGraph theoretical analysisT1D.Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes
Saggar M, Tsalikian E, Mauras N, Mazaika P, White NH, Weinzimer S, Buckingham B, Hershey T, Reiss AL. Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes. Diabetes 2016, 66: 754-762. PMID: 27702833, PMCID: PMC5319714, DOI: 10.2337/db16-0414.Peer-Reviewed Original ResearchConceptsControl subjectsIntrinsic connectivityAge-matched control subjectsYoung childrenBrain intrinsic connectivityResting-state functional MRI dataType 1 diabetesSeed-based analysisCognitive functioningBlood glucoseSustained dysregulationOverall group differencesLarge multisite studyT1DYounger ageFunctional MRI dataCognitive deficitsType 1Cognitive functionObserved positive associationDiabetesMultisite studyCompensatory roleGroup differencesBrain
2013
Effectiveness of a Spanish Language Clinic for Hispanic Youth with Type 1 Diabetes
Palau-Collazo MM, Rose P, Sikes K, Kim G, Benavides V, Urban A, Weinzimer S, Tamborlane W. Effectiveness of a Spanish Language Clinic for Hispanic Youth with Type 1 Diabetes. Endocrine Practice 2013, 19: 800-804. PMID: 23757616, DOI: 10.4158/ep13004.or.Peer-Reviewed Original ResearchConceptsBody mass indexMean baseline glycated hemoglobin levelBaseline glycated hemoglobin levelHispanic pediatric patientsTarget HbA1c levelDuration of diabetesGlycated hemoglobin levelsType 1 diabetesHbA1c levelsPediatric patientsHemoglobin levelsHispanic patientsMass indexPatientsMetabolic controlType 1Pilot studyClinicDiabetesT1DLanguage clinicPreliminary findingsHispanic familiesHispanic youthGroup
2008
Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple‐daily injection therapy
Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple‐daily injection therapy. Pediatric Diabetes 2008, 10: 91-96. PMID: 19175899, DOI: 10.1111/j.1399-5448.2008.00476.x.Peer-Reviewed Original ResearchConceptsContinuous glucose monitorType 1 diabetesMDI usersCSII usersContinuous subcutaneous insulin infusionMultiple daily injection therapySubcutaneous insulin infusionTreatment of childrenGlucose monitorContinuous glucose monitoring systemLong-term useInjection therapyClinical factorsGlucose monitoring systemInsulin infusionAmbulatory settingWeek 22Week 1Pilot studyWkT1DDiabetesChildrenSatisfaction surveyDaily use
2007
Continuous Glucose Monitoring in Children with Type 1 Diabetes
Buckingham B, Beck R, Tamborlane W, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy K, Tansey M, Weinzimer S, Wysocki T. Continuous Glucose Monitoring in Children with Type 1 Diabetes. The Journal Of Pediatrics 2007, 151: 388-393.e2. PMID: 17889075, PMCID: PMC2045068, DOI: 10.1016/j.jpeds.2007.03.047.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringContinuous glucose monitorReal-time continuous glucose monitoringGlucose monitoringMean hemoglobin A1cSevere skin reactionsType 1 diabetesGlucose monitorContinuous glucose monitoring systemInsulin pump usersDaily useGlycemic controlHemoglobin A1cDaily treatmentGlucose monitoring systemSkin reactionsWeek 9Glucose valuesBaseline levelsType 1WeeksPump usersT1DHigh satisfactionChildren